ContextVision (CONTX) Aktievy
ContextVision AB (publ) är ett mjukvaruföretag som tillhandahåller bildanalys och bildbehandling för medicinska system i Asien, Europa och Amerika. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
CONTX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ContextVision AB (publ) Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | NOK 3.56 |
| 52 veckors högsta | NOK 6.10 |
| 52 veckors lägsta | NOK 2.70 |
| Beta | 0.22 |
| 1 månads förändring | 1.71% |
| 3 månaders förändring | -5.32% |
| 1 års förändring | -41.64% |
| 3 års förändring | -59.08% |
| 5 års förändring | -78.02% |
| Förändring sedan börsintroduktionen | -3.78% |
Senaste nyheter och uppdateringar
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.Recent updates
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
Nov 19
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
Nov 09We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
Sep 09Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
Aug 30Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
May 09There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Mar 04
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
Feb 25Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
Feb 15There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Sep 02ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Mar 11ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
Feb 22ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 18Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
Jan 26When Should You Buy ContextVision AB (publ) (OB:CONTX)?
Jun 22Aktieägarnas avkastning
| CONTX | NO Healthcare Services | NO Marknad | |
|---|---|---|---|
| 7D | -3.0% | -2.2% | 1.9% |
| 1Y | -41.6% | -8.2% | 26.4% |
Avkastning vs industri: CONTX presterade sämre än Norwegian Healthcare Services branschen som gav -8.2 % under det senaste året.
Avkastning vs Marknaden: CONTX presterade sämre än Norwegian marknaden som gav 26.4 % under det senaste året.
Prisvolatilitet
| CONTX volatility | |
|---|---|
| CONTX Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 6.6% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in NO Market | 11.6% |
| 10% least volatile stocks in NO Market | 3.3% |
Stabil aktiekurs: CONTX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Norwegian.
Volatilitet över tid: CONTX s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1989 | 43 | Gerald Potzsch | www.contextvision.com |
ContextVision AB (publ) är ett mjukvaruföretag som tillhandahåller bildanalys och bildbehandling för medicinska system i Asien, Europa och Amerika. Företaget erbjuder bildkvalitetslösningar för ultraljud, och dess Rivent-plattform omfattar Rivent, en 2D-bildförbättring, Rivent Plus, en premiumprodukt för 2D-bildförbättring, Rivent 3D, en lösning för att förbättra bildkvaliteten för 3D-ultraljud, och Rivent Mobile, en 2D-bildförbättring för handhållna enheter för diagnostik inom olika områden, inklusive radiologi, kardiologi, kvinnohälsa, veterinärmedicin och vårdnära applikationer. Företaget tillhandahåller också Altumira-plattformen som har scatter-korrigering och förbättrar radiografi genom att möjliggöra minskning av stråldosen samtidigt som bildkvaliteten förbättras, till exempel Altumira för statiska applikationer och Altumira Plus för dynamiska applikationer.
ContextVision AB (publ) Sammanfattning av grunderna
| CONTX grundläggande statistik | |
|---|---|
| Börsvärde | NOK 268.69m |
| Vinst(TTM) | NOK 785.59k |
| Intäkter(TTM) | NOK 110.79m |
338.2x
P/E-förhållande2.4x
P/S-förhållandeÄr CONTX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CONTX resultaträkning (TTM) | |
|---|---|
| Intäkter | SEK 110.99m |
| Kostnad för intäkter | SEK 64.54m |
| Bruttovinst | SEK 46.46m |
| Övriga kostnader | SEK 45.67m |
| Intäkter | SEK 787.00k |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 08, 2026
| Vinst per aktie (EPS) | 0.011 |
| Bruttomarginal | 41.86% |
| Nettovinstmarginal | 0.71% |
| Skuld/egenkapitalförhållande | 0% |
Hur har CONTX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/05 17:09 |
| Aktiekurs vid dagens slut | 2026/05/05 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
ContextVision AB (publ) bevakas av 3 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |